Overview
On 10 June 2003, orphan designation (EU/3/03/145) was granted by the European Commission to Eurogen Pharmaceuticals Limited, United Kingdom, for rubitecan for the treatment of pancreatic cancer.
Key facts
Active substance |
Rubitecan
|
Intended use |
Treatment of pancreatic cancer
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/03/145
|
Date of designation |
10/06/2003
|
Sponsor |
Eurogen Pharmaceuticals Ltd
The Gloucestershire Innovation Centre Southgate House Southgate Street Gloucester GL1 1UD United Kingdom Telephone: +44 (0)1452 563 026 Telefax: +44 (0)1452 563 028 E-mail: Ljohnson@eurogenpharma.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: